NDAORALTABLETPriority Review
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
19
Data completeness
7/8 — Comprehensive
Priority Review
CIBINQO (abrocitinib) by Pfizer is janus kinase inhibitors [moa]. Approved for atopic dermatitis. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIBINQO (abrocitinib) is an oral Janus Kinase (JAK) inhibitor tablet developed by Pfizer and approved by the FDA on January 14, 2022. It is indicated for the treatment of atopic dermatitis and represents a small-molecule approach to modulating immune dysfunction. The drug works by inhibiting JAK enzymes, which are key signaling proteins in inflammatory and immune pathways, thereby reducing disease-driven inflammation. CIBINQO is part of the growing JAK inhibitor class, which has expanded treatment options for moderate-to-severe inflammatory conditions.
$0.0BPart D
9.7 years to LOEMechanism of Action
Janus Kinase Inhibitors
Pharmacologic Class:
Janus Kinase Inhibitor
Indications (1)
Clinical Trials (19)
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
Started Jan 2026
150 enrolled
Atopic DermatitisAtopic Dermatitis, UnspecifiedDermatitis, Atopic
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Started Dec 2025
500 enrolled
Atopic Dermatitis
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Started Jul 2025
150 enrolled
Eczema
Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID
Started Dec 2024
46 enrolled
Post-COVID ConditionFatigue Symptom
Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)
Started Jul 2024
200 enrolled
Dermatitis, AtopicDermatitisEczema+3 more
Worked on CIBINQO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.